Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Novo Nordisk A/S ADR
(NY:
NVO
)
135.60
-5.27 (-3.74%)
Streaming Delayed Price
Updated: 1:28 PM EDT, Jul 17, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Novo Nordisk A/S ADR
< Previous
1
2
...
28
29
30
31
32
33
34
35
36
...
54
55
Next >
'Airbnb Has Foundational Cracks', Disney+ Follows Netflix On Subscription Sharing Crackdown, Microsoft's Nadella Criticizes Google's Exclusive Content Deals: Today's Top Stories
October 03, 2023
Benzinga
Via
Benzinga
Novo Nordisk Weight Loss Drug Patent Battle Against Viatris - Emerges As Winner
October 03, 2023
Novo Nordisk A/S (NYSE: NVO) successfully defended two pivotal patent claims linked to the main ingredient in its popular weight-loss and diabetes drugs,
Via
Benzinga
Topics
Intellectual Property
Exposures
Intellectual Property
Meet Soleno Therapeutics, The Company Whose Hunger Suppressant Sent Shares Flying 505%
October 03, 2023
Soleno Therapeutics is working on a treatment for Prader Willi syndrome, a genetic disease that causes obesity.
Via
Investor's Business Daily
Why Shares of Structure Therapeutics Are Up Monday
October 02, 2023
The stock climbed for the second straight day after the company reported positive trial data for its weight-loss therapy drug.
Via
The Motley Fool
$100 Invested In This Stock 10 Years Ago Would Be Worth $500 Today
September 28, 2023
Via
Benzinga
Is Novo Nordisk a Good Passive Income Stock?
September 28, 2023
Producing cash isn't a problem for this pharma giant.
Via
The Motley Fool
NYSE:NVO stands out as a growth opportunity that won't break the bank.
September 26, 2023
NYSE:NVO, a growth stock which is not overvalued.
Via
Chartmill
Big Pharma's Weight Loss Drugs Vs. Snacking Industry: Who Will Prevail?
October 02, 2023
The rising prevalence of obesity and diabetes drugs like Novo Nordisk A/S's (NYSE: NVO) Wegovy and Ozempic is triggering concerns among investors about the future of the snacking industry.
Via
Benzinga
Stable Giants: 3 Bigwig Biotech Stocks for Consistent Returns
October 02, 2023
These biotech stocks, Thermo Fisher, Novo Nordisk, and Eli Lilly, will bring consistent returns in the volatile biotech sector.
Via
InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For October 2, 2023
October 02, 2023
Via
Benzinga
Don't overlook NYSE:NVO—a stock with solid growth prospects and a reasonable valuation.
September 22, 2023
In the world of growth stocks, NYSE:NVO shines as a value proposition.
Via
Chartmill
Cardiol Therapeutics 76% YTD Gain Is A Bullish Signal Ahead Of Expected Phase III Trial Announcements ($CRDL)
October 02, 2023
Via
AB Newswire
Topics
Death
Exposures
Death
Product Safety
What A Government Shutdown Could Mean For You
September 30, 2023
In a nail-biting development amid fears of a government shutdown, the House has passed a bipartisan bill, narrowly averting the blackout as the midnight deadline looms.
Via
Benzinga
These 5 Stocks Are Setting Up This Buying Opportunity After Strong Runs
September 30, 2023
Stocks can offer a new buying opportunity with a pullback to the 50-day line.
Via
Investor's Business Daily
Why Shares of Structure Therapeutics Are Soaring on Friday
September 29, 2023
The company reported positive results from an early-stage clinical trial for its weight-loss therapy candidate.
Via
The Motley Fool
Newcomer Structure Throws Down The Gauntlet In Obesity Treatment -- Shares Soar 66%
September 29, 2023
The company is working on a pill to help weight loss, rivaling shots from Novo and, possibly, Lilly.
Via
Investor's Business Daily
Why Is Obesity Focused Structure Therapeutics Stock Trading Higher Today?
September 29, 2023
Structure Therapeutics Inc (NASDAQ: GPCR) released results from the Phase 1b multiple ascending dose (MAD) study of GSBR-1290 in healthy, overweight, or
Via
Benzinga
Novo Nordisk Targets High Demand Indian Market For Its Popular Obesity Drugs Like Wegovy
September 29, 2023
Danish pharma giant Novo Nordisk A/s (NYSE: NVO) has set its sights on India for the introduction of its breakthrough
Via
Benzinga
Why Abbott Says It Won't Be A Casualty Of The Weight-Loss Battle
September 28, 2023
Abbott and Dexcom stocks have tumbled as GLP-1 drugs have gripped the nation.
Via
Investor's Business Daily
3 Biotech Stocks to Watch Ahead of Potential Obesity Drug Approvals
September 28, 2023
The demand for biotech stocks is intense and is likely to only greatly increase going forward, especially in the United States.
Via
InvestorPlace
Despite Being Costly, Ozempic, Wegovy Prescriptions Surge 300% Over Three Years
September 28, 2023
An analytics firm Trilliant Health analysis revealed a significant surge in prescriptions for diabetes and obesity drugs like Ozempic and Wegovy during the
Via
Benzinga
Diabetes Prevalence Continues To Rise – Better Therapeutics' Digital Treatment Could Help Change This Trajectory
September 28, 2023
With the ever-increasing prevalence and staggering economic burden, the demand for innovative solutions to treat diabetes has never been higher
Via
Benzinga
Popular Weight Loss Drugs Ozempic and Wegovy Alert: FDA Adds Intestinal Blockage Warning
September 27, 2023
In a significant development, the FDA has updated the labeling for Novo Nordisk A/S's (NYSE: NVO) Ozempic, a diabetes drug known for its weight loss side effect, to include warnings about reports of...
Via
Benzinga
Exposures
Product Safety
Apple Defends Its $19B Google Search Deal, Hollywood's Writers Secure Credit For AI Training, China's Ambitious Chip Fund Faces Headwinds: Today's Top Stories
September 27, 2023
Benzinga Alibaba's Logistics Arm Cainiao Files For Hong Kong IPO
Via
Benzinga
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Weight Loss Drugs Like Wegovy Could Have Linked Anesthesia Complications, European Medicines Agency To Investigate
September 27, 2023
The European Medicines Agency (EMA) is set to address concerns related to patients taking drugs such as Novo Nordisk A/S's (NYSE
Via
Benzinga
2 Magnificent Dividend Stocks to Buy Right Now
September 26, 2023
These two expensive dividend stocks are worth the price of admission.
Via
The Motley Fool
Which High-Profile Stock-Split Stock Is the Cheapest? Get Ready to Be Shocked...
September 25, 2023
Among Nvidia, Amazon, DexCom, Shopify, Alphabet, Tesla, Palo Alto Networks, Monster Beverage, and Novo Nordisk, there's one clear-cut stock-split stock that's notably cheaper than the rest.
Via
The Motley Fool
WW International Shares Jump On BCBS Michigan's Revised Authorization For Wegovy, Other Weight Loss Drugs
September 22, 2023
Via
Benzinga
Stock Market Falls Into Correction On Hawkish Fed: Weekly Review
September 22, 2023
Treasury yields surged to long-term highs, while leading stocks buckled.
Via
Investor's Business Daily
Where Will Novo Nordisk Stock Be in 5 Years?
September 22, 2023
Weight-loss treatments are a big part of Novo Nordisk's business and could be key to its growth for years to come.
Via
The Motley Fool
< Previous
1
2
...
28
29
30
31
32
33
34
35
36
...
54
55
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.